Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau121zxn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	JAN 26	CA/CAPLUS - Expanded patent coverage to include the Russian Agency for Patents and Trademarks (ROSPATENT)
NEWS	18	FEB 10	STN Patent Forums to be held in March 2005
NEWS	19	FEB 16	STN User Update to be held in conjunction with the 229th ACS National Meeting on March 13, 2005

NEWS EXPRESS	JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:40:19 ON 16 FEB 2005

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:40:27 ON 16 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 FEB 2005 HIGHEST RN 831913-30-5
DICTIONARY FILE UPDATES: 15 FEB 2005 HIGHEST RN 831913-30-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\STNEXP4\QUERIES\09595218.str



chain nodes :
8 9 10 11 12 14 18
ring nodes :
1 2 3 4 5 6 13 15 17

chain bonds :
5-8 8-10 9-10 10-11 11-12 12-13 14-15 17-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-15 13-17
exact/norm bonds :
5-8 8-10 9-10 10-11 11-12 12-13 13-15 13-17 14-15 17-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:Cb,Ak

G2:C,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:CLASS 15:Atom 17:Atom 18:CLASS

L1 STRUCTURE UPLOADED

=> dis l1
L1 HAS NO ANSWERS
L1 STR



G1 Cb,Ak
G2 C,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam
SAMPLE SEARCH INITIATED 10:40:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 682 TO ITERATE

100.0% PROCESSED 682 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        12074 TO    15206
PROJECTED ANSWERS:               1 TO       80

L2            1 SEA SSS SAM L1

=> dis

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   227473-21-4  REGISTRY
CN   2-Propenamide, N-[4-(2,5-dihydro-2,5-dioxo-3-phenyl-1H-pyrrol-1-yl)butyl]-
     3-(3-pyridinyl)- (9CI)  (CA INDEX NAME)
FS   3D CONCORD
MF   C22 H21 N3 O3
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); USES
       (Uses)
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

              2 REFERENCES IN FILE CA (1907 TO DATE)
              2 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> s l1 full
FULL SEARCH INITIATED 10:41:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  14184 TO ITERATE

100.0% PROCESSED   14184 ITERATIONS                          41 ANSWERS
SEARCH TIME: 00.00.02

L3           41 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               163.17     163.38

FILE 'HCAPLUS' ENTERED AT 10:41:16 ON 16 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Feb 2005 VOL 142 ISS 8
FILE LAST UPDATED: 15 Feb 2005 (20050215/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 4 L3

=> dis l4 1-4 bib abs hitstr

L4 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:472319 HCAPLUS
DN 141:47322
TI Sulfur heterocycle-condensed pyrimidinedione derivatives, prodrugs of them, JNK inhibitors containing them, and pharmaceuticals containing them
IN Ito, Fumio; Kimura, Hiroyuki; Ikata, Hideki; Kitamura, Shuji; Kawamoto, Tomohiro; Abe, Hidenori
PA Takeda Chemical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 117 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2004161716	A2	20040610	JP 2002-332027	20021115
PRAI	JP 2002-332027		20021115		

OS MARPAT 141:47322
GI



I

AB The derivs., useful for prevention and treatment of diseases involving JNK, e.g. cardiac failure, hypertension, rheumatoid arthritis, asthma, Alzheimer's disease, ischemia, etc., are represented by I [R = H, (un)substituted hydrocarbyl, (un)substituted heterocyclyl; X1, X2 =

(un)substituted C2-4 alkylene; X3 = direct bond, (un)substituted C1-5 alkylene, (un)substituted C2-4 alkenylene; Y = direct bond, (un)substituted divalent cyclic group; Q = direct bond, O, S, NR1 [R1 = H, (un)substituted lower alkyl]; L = direct bond, CONR2 [R2 = H, (un)substituted lower alkyl]; ring A = (un)substituted N-heterocycle; n = 0, 1, 2]. JNK inhibitors contain I, their salts, or prodrugs of I. Thus, IC50 of 4-(6-aminopyridin-3-yl)-N-[3-(1,1,6,8-tetraoxo-9-phenyl-1,3,4,8-tetrahydro-2H-1λ6-pyrimido[6,1-b][1,3]thiazin-7-yl)propyl]benzamide hydrochloride (II preparation given) against human JNK1 was 0.00082 μM. Capsules and tablets containing II were also formulated.

IT **701214-80-4P 701215-93-2P 701216-00-4P 701216-12-8P 701216-13-9P 701216-14-0P 701216-15-1P 701216-16-2P 701216-17-3P 701216-18-4P 701216-19-5P 701216-20-8P 701216-22-0P 701216-23-1P 701216-24-2P 701216-25-3P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfur heterocycle-condensed pyrimidinedione derivs. as JNK inhibitors)

RN 701214-80-4 HCAPLUS

CN Benzamide, N-[3-(3,4-dihydro-1,1-dioxido-6,8-dioxo-9-phenyl-2H,6H-pyrimido[6,1-b][1,3]thiazin-7(8H)-yl)propyl]-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 701215-93-2 HCAPLUS

CN Carbamic acid, [5-[4-[[[3-(3,4-dihydro-1,1-dioxido-6,8-dioxo-9-phenyl-2H,6H-pyrimido[6,1-b][1,3]thiazin-7(8H)-yl)propyl]amino]carbonyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 701216-00-4 HCAPLUS

CN 4-Pentenamide, N-[3-(3,4-dihydro-1,1-dioxido-6,8-dioxo-9-phenyl-2H,6H-pyrimido[6,1-b][1,3]thiazin-7(8H)-yl)propyl]-5-phenyl-5-(3-pyridinyl)-,

mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 701215-99-8
CMF C32 H32 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 701216-12-8 HCAPLUS
CN Carbamic acid, [5-[3-[[[3-(3,4-dihydro-1,1-dioxido-6,8-dioxo-9-phenyl-2H,6H-pyrimido[6,1-b][1,3]thiazin-7(8H)-yl)propyl]amino]carbonyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 701216-13-9 HCAPLUS
CN Carbamic acid, cyclohexyl[5-[4-[[[3-(3,4-dihydro-1,1-dioxido-6,8-dioxo-9-phenyl-2H,6H-pyrimido[6,1-b][1,3]thiazin-7(8H)-yl)propyl]amino]carbonyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 701216-14-0 HCAPLUS
CN Carbamic acid, [5-[4-[[[3-(3,4-dihydro-6,8-dioxo-9-phenyl-2H,6H-pyrimido[6,1-b][1,3]thiazin-7(8H)-yl)propyl]amino]carbonyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 701216-15-1 HCAPLUS
CN Carbamic acid, [5-[3-[[[3-(3,4-dihydro-6,8-dioxo-9-phenyl-2H,6H-pyrimido[6,1-b][1,3]thiazin-7(8H)-yl)propyl]amino]carbonyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 701216-16-2 HCAPLUS
CN Carbamic acid, [5-[4-[[[3-(3,4-dihydro-6,8-dioxo-2H,6H-pyrimido[6,1-b][1,3]thiazin-7(8H)-yl)propyl]amino]carbonyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 701216-17-3 HCAPLUS
CN Benzamide, 4-(6-amino-3-pyridinyl)-N-[3-(3,4-dihydro-1,1-dioxido-6,8-dioxo-9-phenyl-2H,6H-pyrimido[6,1-b][1,3]thiazin-7(8H)-yl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 701216-18-4 HCAPLUS
CN Benzamide, 4-(6-amino-3-pyridinyl)-N-[3-(3,4-dihydro-1,1-dioxido-6,8-dioxo-2H,6H-pyrimido[6,1-b][1,3]thiazin-7(8H)-yl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 701216-19-5 HCAPLUS
CN Benzamide, 4-(6-amino-3-pyridinyl)-N-[3-(3,4-dihydro-6,8-dioxo-9-phenyl-2H,6H-pyrimido[6,1-b][1,3]thiazin-7(8H)-yl)propyl]- (9CI) (CA INDEX NAME)



RN 701216-20-8 HCAPLUS
CN Benzamide, 4-(6-amino-3-pyridinyl)-N-[3-(3,4-dihydro-6,8-dioxo-2H,6H-pyrimido[6,1-b][1,3]thiazin-7(8H)-yl)propyl]- (9CI) (CA INDEX NAME)



RN 701216-22-0 HCAPLUS
CN Benzamide, 3-(6-amino-3-pyridinyl)-N-[3-(3,4-dihydro-6,8-dioxo-9-phenyl-2H,6H-pyrimido[6,1-b][1,3]thiazin-7(8H)-yl)propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 701216-21-9
CMF C28 H27 N5 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 701216-23-1 HCAPLUS
CN Benzamide, N-[3-(3,4-dihydro-1,1-dioxido-6,8-dioxo-9-phenyl-2H,6H-pyrimido[6,1-b][1,3]thiazin-7(8H)-yl)propyl]-4-[6-(phenylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 701216-24-2 HCAPLUS
CN Benzamide, 4-[6-(cyclohexylamino)-3-pyridinyl]-N-[3-(3,4-dihydro-1,1-dioxido-6,8-dioxo-9-phenyl-2H,6H-pyrimido[6,1-b][1,3]thiazin-7(8H)-yl)propyl]- (9CI) (CA INDEX NAME)



RN 701216-25-3 HCAPLUS
CN Benzeneacetamide, N-[5-[4-[[[3-(3,4-dihydro-1,1-dioxido-6,8-dioxo-2H,6H-pyrimido[6,1-b][1,3]thiazin-7(8H)-yl)propyl]amino]carbonyl]phenyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



IT **701214-82-6 701214-85-9 701214-86-0**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of sulfur heterocycle-condensed pyrimidinedione derivs. as JNK inhibitors)
RN 701214-82-6 HCAPLUS
CN Benzamide, 4-(6-amino-3-pyridinyl)-N-[3-(3,4-dihydro-1,1-dioxido-6,8-dioxo-

9-phenyl-2H,6H-pyrimido[6,1-b][1,3]thiazin-7(8H)-yl)propyl]- (9CI) (CA INDEX NAME)



RN 701214-85-9 HCAPLUS
CN Benzamide, 3-(6-amino-3-pyridinyl)-N-[3-(3,4-dihydro-1,1-dioxido-6,8-dioxo-9-phenyl-2H,6H-pyrimido[6,1-b][1,3]thiazin-7(8H)-yl)propyl]- (9CI) (CA INDEX NAME)



RN 701214-86-0 HCAPLUS
CN Benzeneacetamide, N-[5-[4-[[[3-(3,4-dihydro-1,1-dioxido-6,8-dioxo-9-phenyl-2H,6H-pyrimido[6,1-b][1,3]thiazin-7(8H)-yl)propyl]amino]carbonyl]phenyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:771327 HCAPLUS
DN 139:271057
TI Use of pyridyl amides as inhibitors of angiogenesis
IN Biedermann, Elfi; Loeser, Roland; Rattel, Benno
PA Fujisawa Deutschland G.m.b.H., Germany
SO Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1348434	A1	20031001	EP 2002-6697	20020327
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	WO 2003080054	A1	20031002	WO 2003-EP3060	20030324
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1487444	A1	20041222	EP 2003-744849	20030324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	EP 2002-6697	A	20020327		
	WO 2003-EP3060	W	20030324		

OS MARPAT 139:271057
GI



I

AB The invention relates to the use of derivs. of Formula I (A = C1-10-alkylene, C2-10-alkenylene, and C2-10-alkinylene; R1 = H, C1-6-alkyl, fluoro, chloro, bromo, and perfluoro-C1-3-alkyl; R2 = H, C1-6-alkyl, and C2-6-alkenyl; and R3 = C1-6-alkyl, (C5-8-cycloalkyl)-C1-6-alkyl, (C5-8-heterocycle)-C1-6-alkyl, C1-6-alkyl-(C5-8-heterocycle)-C1-6-alkyl, and C1-5-alkylcarbonyl-(C5-8-heterocycle)-C1-6-alkyl) in the manufacture of a pharmaceutical composition for the treatment of a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred, and to the prevention thereof. The disease to be treated include rheumatoid arthritis, inflammatory disorder, macular degeneration, especially age-related macular degeneration, psoriasis; retinopathy, especially proliferative retinopathy and diabetic retinopathy, preneoplastic lesions and hyperplasia, especially benign prostatic hyperplasia and venous neointimal hyperplasia. A compound of Formula I may also be used for diagnostic purposes in vitro.

IT **227473-14-5 227473-28-1 606130-79-4**
RL: DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of pyridyl amides as inhibitors of angiogenesis for disease treatment and diagnosis in relation to inhibition of VEGF production)

RN 227473-14-5 HCAPLUS

CN 2-Propenamide, N-[4-(2,6-dioxo-4-phenyl-1-piperidinyl)butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-28-1 HCAPLUS
CN 2-Propenamide, N-[4-[2,6-dioxo-4-(phenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 606130-79-4 HCAPLUS
CN 2-Propenamide, N-[4-(2,6-dioxo-3-phenyl-1-piperidinyl)butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:690954 HCAPLUS
DN 131:307106
TI Use of vitamin PP compounds as cytoprotective agents in chemotherapy
IN Biedermann, Elfi; Hasmann, Max; Loser, Roland; Rattel, Benno; Reiter, Friedemann; Schein, Barbara; Schemainda, Isabel; Seibel, Klaus; Vogt, Klaus; Wosikowski, Katja
PA Klinge Pharma GmbH, Germany
SO PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9953920	A1	19991028	WO 1999-EP2686	19990421

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,

DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 19818044	A1	19991028	DE 1998-19818044	19980422	
EP 1031564	A1	20000830	EP 1999-103814	19990226	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
AU 9939282	A1	19991108	AU 1999-39282	19990421	
EP 1079832	A1	20010307	EP 1999-922119	19990421	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
JP 2002512190	T2	20020423	JP 2000-544324	19990421	
WO 2000050399	A1	20000831	WO 2000-EP1628	20000228	
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
EP 1154998	A1	20011121	EP 2000-907642	20000228	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2002537380	T2	20021105	JP 2000-600982	20000228	
US 2002160968	A1	20021031	US 2001-935772	20010823	
US 6506572	B2	20030114			
PRAI DE 1998-19818044	A	19980422			
EP 1999-103814	A	19990226			
WO 1999-EP2686	W	19990421			
WO 2000-EP1628	W	20000228			

OS MARPAT 131:307106

AB The invention relates to the use of vitamin PP compds. and/or compds. with anti-pellagra activity such as for example nicotinic acid (niacin), and nicotinamide (niacin-amide, vitamin PP, vitamin B3) for the reduction, elimination or prevention of side-effects of different degrees as well as for neutralization of acute side-effects in immunosuppressive or cancerostatic chemotherapy or diagnosis, especially with substituted pyridine carboxamides, as well as combination medicaments with an amount of compds. with vitamin B3 and/or anti-pellagra activity and chemotherapeutic agents are especially considered in the mentioned chemotherapies and indications. Nicotinamide at 500 mg/kg twice daily protected mice treated i.p. with antitumor N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide. There were no deaths in the nicotinamide-treated mice and the strong reduction of leukocytes was completely prevented.

IT **227473-12-3 227473-14-5 227473-16-7**
227473-18-9 227473-19-0 227473-20-3
227473-21-4 227473-23-6 227473-25-8
227473-27-0 227473-28-1 227473-30-5
227473-32-7 227473-33-8 227473-34-9
227473-35-0 227473-36-1 227473-38-3
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(vitamin PP compds. as cytoprotective agents in chemotherapy)

RN 227473-12-3 HCAPLUS

CN 2-Propenamide, N-[4-(2,5-dihydro-2,5-dioxo-3,4-diphenyl-1H-pyrrol-1-yl)butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-14-5 HCAPLUS

CN 2-Propenamide, N-[4-(2,6-dioxo-4-phenyl-1-piperidinyl)butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-16-7 HCAPLUS

CN 2-Propenamide, N-[4-(1,3-dihydro-1,3-dioxo-4,5,6,7-tetraphenyl-2H-isoindol-2-yl)butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-18-9 HCAPLUS

CN 2-Propenamide, 3-(3-pyridinyl)-N-[4-[2,4,5-trioxo-3-(phenylmethyl)-1-imidazolidinyl]butyl]- (9CI) (CA INDEX NAME)



RN 227473-19-0 HCAPLUS
CN 2-Propenamide, 3-(3-pyridinyl)-N-[4-(5,6,10,10a-tetrahydro-1,3,10-trioxo-1H,4H-acenaphtho[1,8a-c]pyrrol-2(3H)-yl)butyl]- (9CI) (CA INDEX NAME)



RN 227473-20-3 HCAPLUS
CN 2-Propenamide, N-[4-(2,5-dioxo-4,4-diphenyl-1-imidazolidinyl)butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-21-4 HCAPLUS
CN 2-Propenamide, N-[4-(2,5-dihydro-2,5-dioxo-3-phenyl-1H-pyrrol-1-yl)butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-23-6 HCAPLUS
CN 2-Propenamide, N-[3-(2,5-dihydro-2,5-dioxo-3,4-diphenyl-1H-pyrrol-1-yl)propyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-25-8 HCAPLUS
CN 2-Propenamide, N-[4-(1,3,3a,4,9,9a-hexahydro-1,3-dioxo-4,9[1',2']-benzeno-2H-benz[f]isoindol-2-yl)butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-27-0 HCAPLUS
CN 2-Propenamide, N-[4-[2,4-dioxo-5-(phenylmethylene)-3-thiazolidinyl]butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-28-1 HCAPLUS
CN 2-Propenamide, N-[4-[2,6-dioxo-4-(phenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-30-5 HCAPLUS
CN 2-Propenamide, N-[6-(2,5-dihydro-2,5-dioxo-3,4-diphenyl-1H-pyrrol-1-yl)hexyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-32-7 HCAPLUS
CN 3-Pyridinepropanamide, N-[4-(2,5-dihydro-2,5-dioxo-3,4-diphenyl-1H-pyrrol-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 227473-33-8 HCAPLUS
CN 2-Propenamide, N-[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-34-9 HCAPLUS
CN 2-Propenamide, N-[4-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)butyl]-3-(1-oxido-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-35-0 HCAPLUS
CN 2-Propenamide, N-[4-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-36-1 HCAPLUS
CN 2-Propenamide, N-[6-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)hexyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-38-3 HCAPLUS
CN 2-Propenamide, N-[2-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)ethyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:404952 HCAPLUS
DN 131:58758
TI Cyclic imide-substituted pyridylalkanecarboxamides, pyridylalkenecarboxamides and pyridylalkynecarboxamides useful as cytostatic and immunosuppressive agents
IN Biedermann, Elfi; Hasmann, Max; Loser, Roland; Rattel, Benno; Reiter, Friedemann; Schein, Barbara; Seibel, Klaus; Vogt, Klaus; Wosikowski, Katja
PA Klinge Pharma G.m.b.H., Germany
SO PCT Int. Appl., 168 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9931087	A1	19990624	WO 1998-EP8267	19981216
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19756212	A1	19990701	DE 1997-19756212	19971217
	ZA 9811231	A	19990608	ZA 1998-11231	19981208
	AU 9924146	A1	19990705	AU 1999-24146	19981216
	EP 1042315	A1	20001011	EP 1998-966634	19981216
	EP 1042315	B1	20040414		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002508367	T2	20020319	JP 2000-539011	19981216
	AT 264321	E	20040415	AT 1998-966634	19981216
	PT 1042315	T	20040831	PT 1998-966634	19981216
	ES 2218881	T3	20041116	ES 1998-966634	19981216
PRAI	DE 1997-19756212	A	19971217		
	WO 1998-EP8267	W	19981216		

OS MARPAT 131:58758
GI



I

AB Pyridine derivs. I [R1 = H, OH, halo, CN, or organic group; R2 = H, halo, CN, alkyl, trifluoromethyl, OH, alkoxy, or aralkoxy; R3 = H, alkyl, alkenyl, alkynyl, OH, alkoxy, or aryloxy; A = (substituted) alkylene, 1,2-cyclopropylene, (substituted) alkenylene, (substituted) alkadienylene, (substituted) hexatrienylene, or ethynylene; D = (substituted) alkylene, (substituted) alkenylene, (substituted) alkynylene (in which 1-3 CH2 units is isosterically replaced by O, S, NR4, CO, SO, or SO2, R4 = H, alkyl, alkenyl, acyl, or alkanesulfonyl); E = N-substituted cyclic imide or N-substituted cyclic sulfonimide; k = 0 or 1] are manufactured for use as cytostatic agents and immunosuppressive agents. Thus, slowing adding 46.9 mmol oxalyl chloride to 20 mmol 3-(3-pyridyl)acrylic acid suspended in CH2Cl2, stirring the mixture with ice-cooling for 30 min and then at room temperature overnight, suspending the resulting acid chloride in CH2Cl2, cooling to 0° under anhydrous conditions, adding 17.6 mmol 4-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)butylamine-HCl in CH2Cl2 and 39.5 mmol Et3N dropwise, and stirring an addnl. 2 h at room temperature gave N-[4-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)butyl]-3-pyridin-3-ylacrylamide.

IT **227473-12-3P 227473-14-5P 227473-16-7P 227473-18-9P 227473-19-0P 227473-20-3P 227473-21-4P 227473-23-6P 227473-27-0P 227473-28-1P 227473-30-5P 227473-32-7P 227473-33-8P 227473-34-9P 227473-36-1P 227473-38-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cyclic imide-substituted pyridyl carboxamides for cytostatic and immunosuppressive agents)

RN 227473-12-3 HCAPLUS

CN 2-Propenamide, N-[4-(2,5-dihydro-2,5-dioxo-3,4-diphenyl-1H-pyrrol-1-yl)butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-14-5 HCAPLUS

CN 2-Propenamide, N-[4-(2,6-dioxo-4-phenyl-1-piperidinyl)butyl]-3-(3-

pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-16-7 HCAPLUS
CN 2-Propenamide, N-[4-(1,3-dihydro-1,3-dioxo-4,5,6,7-tetraphenyl-2H-isoindol-2-yl)butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-18-9 HCAPLUS
CN 2-Propenamide, 3-(3-pyridinyl)-N-[4-[2,4,5-trioxo-3-(phenylmethyl)-1-imidazolidinyl]butyl]- (9CI) (CA INDEX NAME)



RN 227473-19-0 HCAPLUS
CN 2-Propenamide, 3-(3-pyridinyl)-N-[4-(5,6,10,10a-tetrahydro-1,3,10-trioxo-1H,4H-acenaphtho[1,8a-c]pyrrol-2(3H)-yl)butyl]- (9CI) (CA INDEX NAME)



RN 227473-20-3 HCAPLUS
CN 2-Propenamide, N-[4-(2,5-dioxo-4,4-diphenyl-1-imidazolidinyl)butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-21-4 HCAPLUS
CN 2-Propenamide, N-[4-(2,5-dihydro-2,5-dioxo-3-phenyl-1H-pyrrol-1-yl)butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-23-6 HCAPLUS
CN 2-Propenamide, N-[3-(2,5-dihydro-2,5-dioxo-3,4-diphenyl-1H-pyrrol-1-yl)propyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-27-0 HCAPLUS
CN 2-Propenamide, N-[4-[2,4-dioxo-5-(phenylmethylene)-3-thiazolidinyl]butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-28-1 HCAPLUS
CN 2-Propenamide, N-[4-[2,6-dioxo-4-(phenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-30-5 HCAPLUS
CN 2-Propenamide, N-[6-(2,5-dihydro-2,5-dioxo-3,4-diphenyl-1H-pyrrol-1-yl)hexyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-32-7 HCAPLUS
CN 3-Pyridinepropanamide, N-[4-(2,5-dihydro-2,5-dioxo-3,4-diphenyl-1H-pyrrol-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 227473-33-8 HCAPLUS
CN 2-Propenamide, N-[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-34-9 HCAPLUS
CN 2-Propenamide, N-[4-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)butyl]-3-(1-oxido-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-36-1 HCAPLUS
CN 2-Propenamide, N-[6-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)hexyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 227473-38-3 HCAPLUS
CN 2-Propenamide, N-[2-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)ethyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **227473-25-8P**
RL: IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cyclic imide-substituted pyridyl carboxamides for cytostatic and immunosuppressive agents)

RN 227473-25-8 HCAPLUS

CN 2-Propenamide, N-[4-(1,3,3a,4,9,9a-hexahydro-1,3-dioxo-4,9[1',2']-benzeno-2H-benz[f]isoindol-2-yl)butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



IT **227473-35-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(precursor; cyclic imide-substituted pyridyl carboxamides for cytostatic and immunosuppressive agents)

RN 227473-35-0 HCAPLUS

CN 2-Propenamide, N-[4-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)butyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	29.56	192.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.92	-2.92

STN INTERNATIONAL LOGOFF AT 10:43:37 ON 16 FEB 2005